Shannon Jones

Sr. Program Manager Adaptive Biotech

[Shannon Jones @SourcingSF]

Proud of our team who’s been working tirelessly on the T-cell testing study and our T-cell test in development! #BeAdaptive #Got2Adapt

[Adaptive Biotech @AdaptiveBiotech]

As part of our new CIRCLE Initiative with @FoundationATCG, Adapters recently joined acclaimed speaker @selenarezvani for a discussion on how to “Be Your Own Fierce Advocate.” She shared inspirational and practical advice for effective self-advocacy. #BeAdaptive #Got2Adapt

[Adaptive Biotech @AdaptiveBiotech]

#blacklivesmatter #embracerace #BeAdaptive #ChangeisAdaptive

[Adaptive Biotech @AdaptiveBiotech]

To our lab and lab support teams in South San Francisco and Seattle, THANK YOU. We’re grateful for your dedication to our mission and patients during these challenging times.
#labweek #labweek2020 #mlpw #Got2Adapt #InThisTogether

[Adaptive Biotech @AdaptiveBiotech]

Thank you, Ryan, and our South San Francisco and Seattle lab and lab support teams. We are grateful for your dedication to our mission and patients during these challenging times. #LabWeek #Got2Adapt #InThisTogether

[Adaptive Biotech @AdaptiveBiotech]

Along with @Microsoft, we will work to decode the immune response to #COVID19 and make all data freely available. Join us and industry leaders, @LABCORP, @illumina and @providence to accelerate this critical effort: https://t.co/qYX2l5bbC3 #InThisTogether

[Adaptive Biotech @AdaptiveBiotech]

.@phalliburton w/ CMO @LanceBaldoMD at the Congressional #PersonalizedMedicine Caucus. Peter shared his story about the impact an early diagnosis had on his family & how it enabled him to find support from others who could relate to his experience. @permedcoalition #patientsfirst

[Adaptive Biotech @AdaptiveBiotech]

#Personalizedmedicine is having an impact on patient care & providing value to the HC system. To realize the benefits, the med community must work to ensure diagnostic tech is incorp. into clinical pathways. Read CMO @lancebaldomd’s thoughts @AJMC_Journal https://t.co/FZmptLClIV

[Adaptive Biotech @AdaptiveBiotech]

Read a real-world story of MRD utility from @CLLSociety: https://t.co/mjP4aNcaNe @clonoSEQ is FDA-cleared to assess MRD in B-ALL & MM patients’ bone marrow; not FDA-cleared in CLL but available as LDT from our CLIA lab. For impt info + test limitations: https://t.co/FzoRRSqJLj

[Adaptive Biotech @AdaptiveBiotech]

Join Katie and Patrick this Tuesday as they give an overview of the #immunoSEQ Assay, discuss how #immunosequencing data has been used to examine autoimmune diseases & opps to help build the TCR-Antigen Map. https://t.co/rZ26mpX4HB RUO. Not for use in diagnostic procedures

[Adaptive Biotech @AdaptiveBiotech]

Join co-founder & Chief Scientific Officer, Harlan Robins, and @genentech Vice President, Cancer Immunology, Ira Mellman at #PMWC20 for a fireside chat on progress, challenges, and what’s next for cancer immunotherapy. Read more about our partnership: https://t.co/c5diof4u10

[Adaptive Biotech @AdaptiveBiotech]

As published in @NatureCancer,@BrighamWomens uses the immunoSEQ Assay to make quantitative, accurate predictions about which primary melanomas are likely to recur and spread. Read the full press release here: https://t.co/7TTxJPrkbX RUO. Not for use in diagnostic procedures.

[Shannon Jones @SourcingSF]

Proud to be a part of the growing @AdaptiveBiotech team as we work towards our common goal to transform the diagnosis and treatment of disease. #got2adapt

[Puget Sound Business Journal @PSBJ]

Adaptive is the third largest biotech company in Seattle by employee count, behind Seattle Genetics (1,060 employees) and Juno Therapeutics (900). https://t.co/FiAVCw58Pb

[Adaptive Biotech @AdaptiveBiotech]

What a year! We launched a successful #IPO, made progress in our TCR-Antigen Map with @Microsoft, announced a #cellulartherapy partnership with @genentech, and broke ground with a new HQ in Seattle. Read more in @PSBJ’s latest piece, and stay tuned for what’s in store for 2020!

[clonoSEQ @clonoSEQ]

Residual disease isn't minimal to patients. Visit #ASH19 booth 1733 to learn more. clonoSEQ is FDA-cleared to assess MRD in MM & B-ALL patients’ bone marrow. For important info incl. test limitations: https://t.co/rzFDaATspW

[Adaptive Biotech @AdaptiveBiotech]

Much of the data at #ASH19 will point to the significance of #MRD in blood cancers. @clonoSEQ is on the path to become the standard of care in MRD measurement; more here: https://t.co/59Q30YQrd4

For important info incl. test limitations: https://t.co/ne1rKu371l

[Adaptive Biotech @AdaptiveBiotech]

Good night ASH. Great first day learning about the latest #MRD data! See you tomorrow morning at the CLL Therapy Combination & Novel Treatment orals https://t.co/ORnRmT8BTP #ASH2019

[Adaptive Biotech @AdaptiveBiotech]

Nice presentation of the CLL 14 study by Kirsten Fischer on the correlation between undetectable MRD and PFS in CLL patients. Read the abstract here: https://t.co/sbdMcacQQj #ASH19

[Adaptive Biotech @AdaptiveBiotech]

This year we are thankful for many things, but we are most thankful for our talented and growing Adaptive team. We have the privilege to work together toward our shared goal to improve patients’ lives #thanksgiving2019